A Phase 1 interventional study of Alisertib and Docetaxel in Advanced Solid Tumors and Adenocarcinoma of the Prostate, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were deemed by the investigator to be medically appropriate candidates for docetaxel therapy.
The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have advanced solid tumors including castration-resistant prostate cancer.
The study enrolled approximately 41 patients. Participants were enrolled to receive:
All participants will receive alisertib (ECT) in dose escalating cohorts, orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 [dose held for pharmacokinetic (PK) collection] along with docetaxel 75 mg/m\^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable AEs or withdrawal of consent.
This multi-center trial is conducted in United States. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. Participants made multiple visits to the clinic, and were contacted every 12 weeks for up to 25.8 months after last dose of study drug for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
Participants with castration-resistant prostate cancer (CRPC) are required to have
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
For CRPC participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m\^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent. The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day).
Drug: Alisertib · Drug: Docetaxel
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From enrollment through 30 days after the last dose of study drug (approximately up to 77 months)
Cmax: Maximum Observed Plasma Concentration for Docetaxel
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration for Docetaxel
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity for Docetaxel
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
Terminal Phase Elimination Half-life (T1/2) for Docetaxel
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Cycles 1 and 2
Cmax: Maximum Observed Plasma Concentration for Alisertib
Time frame: Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
Time frame: Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Day 7 Over the Dosing Interval for Alisertib
Time frame: Prior to dosing on Day 1 and Day 5 or 7 and at multiple time points (up to 12 hours) post-dose in Cycle 1
Overall Response Rate (ORR) Assessed for Overall Participant Population
ORR is defined as percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by response evaluation criteria in solid tumors (RECIST) v 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in sum of longest diameter (LD) of target lesions in reference to Baseline. RECIST-Evaluable Population is subset of safety population who had measurable disease by RECIST v 1.1 at baseline and had at least 1 post baseline response. prostate specific antigen (PSA)-Evaluable Population is subset of the safety population who had a baseline PSA reference value (\>5 ng/mL) and at least 12 weeks post-baseline PSA assessment for participants with no decline from baseline, or PSA progression within 12 weeks of treatment for participants with PSA decline from baseline.
Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Overall Response Rate for Prostate Cancer Participants
ORR is defined as percentage of participants who achieved CR or PR as assessed by either RECIST v 1.1 or PSA response by prostate cancer working group 2 (PCWG2) criteria. According to RECIST v 1.1, CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: ≥30% decrease in sum of LD of target lesions in reference to Baseline sum LD. PSA response by PCWG2 is defined as PSA at least 50% decrease in PSA value from baseline for 2 consecutive evaluations. PCWG2 defines PSA progression as the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later.
Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Best Overall Response Rate Assessed by RECIST Criteria
Best response rate is defined as the percentage of participants with CR, PR, CR+PR, stable disease (SD) and progressive disease (PD) as assessed by RECIST criteria 1.1 for target lesions and assessed by CT, PET or MRI. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Best Overall Response Rate Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria
Best Response Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria PSA response is defined as at least 50% decrease in PSA value from baseline for 2 consecutive evaluations.
Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Duration of Response
Duration of response is defined as the time from the date of first documentation of a response to the date of first documented progressive disease (PD), or censored at last SD or better.
Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Duration of Stable Disease (SD)
Duration of SD is defined as the time from first dose to first PD, or censored at last SD or better.
Time frame: Baseline up to Cycle 36 (21-day cycles) until disease progression, death or EOT (approximately up to 24.8 months)
Participants took part in the study at 4 investigative sites in the United States from 17 August 2010 to 04 January 2017.
| Milestone | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 15 | 5 | 3 | 2 | 4 | 2 | 4 |
| Completed | 4 | 5 | 1 | 1 | 2 | 4 | 2 | 2 |
| Not completed | 2 | 10 | 4 | 2 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Initiation of alternative therapy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 2 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing participants | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| AEs | 6 | 15 | 5 | 3 | 2 | 4 | 2 | 4 |
| SAEs | 3 | 8 | 3 | 2 | 1 | 3 | 2 | 2 |
| ng/mL | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2392.7 ± 60.2 | 1730.4 ± 26.5 | 1587.0 ± 34.1 | 1717.6 ± 51.9 | 3751.4 ± 80.8 | 1159.9 ± 13.8 | 2232.9 ± 19.8 | 1386.6 ± 47.0 |
| Cycle 2 Day 1 | 1825.1 ± 25.9 | 1957.0 ± 23.4 | 2146.6 ± 19.4 | 3299.9 ± 0.9 | 1649.7 ± 19.1 | 1061.6 ± 24.8 | 2504.6 ± 28.0 | 1627.8 ± 17.2 |
| hr*ng/mL | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2328.3 ± 69.5 | 1925.7 ± 21.4 | 1750.1 ± 23.1 | 2163.4 ± 52.8 | 1830.0 ± NA | 1593.1 ± 14.0 | 2394.6 ± 2.7 | 1579.8 ± 45.4 |
| Cycle 2 Day 1 | 1750.8 ± 23.1 | 2416.4 ± 23.7 | 25.5 ± 2174.6 | 7811.5 ± 87.5 | 1622.8 ± 35.0 | 1596.0 ± 19.9 | 2895.7 ± 16.3 | 2510.0 ± NA |
| hr*ng/mL | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2653.3 ± 68.1 | 2240.6 ± 23.9 | 2007.3 ± 15.7 | 3570.0 ± NA | 2130.0 ± NA | 1734.7 ± 9.6 | 2600.0 ± 0.0 | 1730.9 ± 53.9 |
| Cycle 2 Day 1 | 1918.0 ± 21.4 | 2632.2 ± 28.0 | 2019.8 ± 10.1 | 4000.0 ± NA | 1785.4 ± 35.6 | 1631.0 ± 9.9 | 3099.0 ± 14.3 | 3120.0 ± NA |
| hr | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 21.80 ± 4.339 | 22.88 ± 4.733 | 24.00 ± 6.934 | 15.60 ± NA | 30.70 ± NA | 16.34 ± 5.684 | 19.25 ± 2.051 | 24.80 ± 6.444 |
| Cycle 2 Day 1 | 24.18 ± 2.050 | 20.73 ± 5.845 | 20.40 ± 2.121 | 16.40 ± NA | 25.10 ± 2.546 | 22.00 ± 2.404 | 16.95 ± 0.636 | 26.00 ± NA |
| nmol/L | Alisertib 10 mg | Alisertib 20 mg | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|---|---|
| Cycle 1 Day 1 | 290.4 ± 22.1 | 557.5 ± 57.3 | 751.6 ± 31.3 | 1346.4 ± 49.8 |
| Cycle 1 Day 5/Day 7 | 435.8 ± 31.0 | 1140.6 ± 44.7 | 1637.9 ± 52.1 | 1766.3 ± 40.1 |
| hr | Alisertib 10 mg | Alisertib 20 mg | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|---|---|
| Cycle 1 Day 1 | 2.050 (2.00 to 3.00) | 4.000 (2.00 to 9.98) | 3.560 (2.00 to 12.00) | 1.500 (1.00 to 7.58) |
| Cycle 1 Day 5/Day 7 | 3.510 (1.87 to 8.22) | 3.030 (2.00 to 9.40) | 2.030 (2.00 to 8.00) | 1.975 (1.08 to 3.00) |
| hr*nmol/L | Alisertib 10 mg | Alisertib 20 mg | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|---|---|
| Cycle 1 Day 1 | 1635.0 ± 28.3 | 3303.0 ± 46.1 | 4387.5 ± 30.1 | 8013.7 ± 43.1 |
| Cycle 1 Day 5/Day 7 | 3052.8 ± 42.0 | 8546.0 ± 49.7 | 13199.1 ± 60.8 | 12630.0 ± 27.7 |
ORR is defined as percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by response evaluation criteria in solid tumors (RECIST) v 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in sum of longest diameter (LD) of target lesions in reference to Baseline. RECIST-Evaluable Population is subset of safety population who had measurable disease by RECIST v 1.1 at baseline and had at least 1 post baseline response. prostate specific antigen (PSA)-Evaluable Population is subset of the safety population who had a baseline PSA reference value (\>5 ng/mL) and at least 12 weeks post-baseline PSA assessment for participants with no decline from baseline, or PSA progression within 12 weeks of treatment for participants with PSA decline from baseline.
| percentage of participants | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) Assessed for Overall Participant Population | 50 (12 to 88) | 10 (0 to 45) | 100 (NA to NA) | 50 (1 to 99) | 0 (0 to 0) | 25 (1 to 81) | 0 (0 to 0) | 50 (1 to 99) |
ORR is defined as percentage of participants who achieved CR or PR as assessed by either RECIST v 1.1 or PSA response by prostate cancer working group 2 (PCWG2) criteria. According to RECIST v 1.1, CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: ≥30% decrease in sum of LD of target lesions in reference to Baseline sum LD. PSA response by PCWG2 is defined as PSA at least 50% decrease in PSA value from baseline for 2 consecutive evaluations. PCWG2 defines PSA progression as the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later.
| percentage of participants | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Overall Response Rate for Prostate Cancer Participants | 50 (12 to 88) | 20 (1 to 72) | — | 100 (NA to NA) | — | 0 (0 to 0) | — | 100 (NA to NA) |
Best response rate is defined as the percentage of participants with CR, PR, CR+PR, stable disease (SD) and progressive disease (PD) as assessed by RECIST criteria 1.1 for target lesions and assessed by CT, PET or MRI. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
| percentage of participants | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Complete Response (CR) | 0 (0 to 0) | 0 (0 to 0) | 100 (NA to NA) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| Partial Response (PR) | 50 (12 to 88) | 11 (0 to 48) | 0 (0 to 0) | 50 (1 to 99) | 0 (0 to 0) | 25 (1 to 81) | 0 (0 to 0) | 50 (1 to 99) |
| CR+PR | 50 (12 to 88) | 11 (0 to 48) | 100 (NA to NA) | 50 (1 to 99) | 0 (0 to 0) | 25 (1 to 81) | 0 (0 to 0) | 50 (1 to 99) |
| Stable Disease (SD) | 50 (12 to 88) | 67 (30 to 93) | 0 (0 to 0) | 0 (0 to 0) | 50 (1 to 99) | 0 (0 to 0) | 0 (0 to 0) | 50 (1 to 99) |
| Progressive Disease (PD) | 0 (0 to 0) | 22 (3 to 60) | 0 (0 to 0) | 50 (1 to 99) | 50 (1 to 99) | 75 (19 to 99) | 100 (NA to NA) | 0 (0 to 0) |
Best Response Assessed by PSA Response by Prostate Cancer Working Group 2 (PCWG2) Criteria PSA response is defined as at least 50% decrease in PSA value from baseline for 2 consecutive evaluations.
| percentage of participants | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| ≥50% Reduction from Baseline | 67 (22 to 96) | 80 (28 to 99) | — | 100 (NA to NA) | — | — | — | — |
| <50% Reduction from Baseline | 33 (4 to 78) | 20 (1 to 72) | — | 0 (0 to 0) | — | — | — | — |
Duration of response is defined as the time from the date of first documentation of a response to the date of first documented progressive disease (PD), or censored at last SD or better.
| days | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Duration of Response | 187 (43 to 187) | 342 (342 to 342) | 830 (830 to 830) | 176 (176 to 176) | — | 79 (79 to 79) | — | NA (1 to 1) |
Duration of SD is defined as the time from first dose to first PD, or censored at last SD or better.
| days | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Duration of Stable Disease (SD) | 253 (85 to 253) | NA (169 to 751) | — | — | 309 (309 to 309) | — | — | 134 (134 to 134) |
Collected over From signing of the informed consent form up to 30 days after the last dose of study drug (up to 25.8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | — | 3/6 (50%) | 6/6 (100%) |
| Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | — | 10/15 (66.7%) | 14/15 (93.3%) |
| Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | — | 3/5 (60%) | 5/5 (100%) |
| Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | — | 2/3 (66.7%) | 3/3 (100%) |
| Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | — | 1/2 (50%) | 2/2 (100%) |
| Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | — | 3/4 (75%) | 4/4 (100%) |
| Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | — | 2/2 (100%) | 2/2 (100%) |
| Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | — | 2/4 (50%) | 4/4 (100%) |
| Event | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 6/15 | 1/5 | 1/3 | 1/2 | 1/4 | 0/2 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/15 | 0/5 | 0/3 | 0/2 | 0/4 | 1/2 | 0/4 |
| Urinary tract infectionInfections and infestations | 0/6 | 1/15 | 1/5 | 0/3 | 0/2 | 0/4 | 1/2 | 0/4 |
| Clostridium difficile colitisInfections and infestations | 0/6 | 0/15 | 0/5 | 0/3 | 0/2 | 1/4 | 1/2 | 0/4 |
| PneumoniaInfections and infestations | 0/6 | 0/15 | 0/5 | 1/3 | 0/2 | 0/4 | 1/2 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 0/15 | 0/5 | 0/3 | 0/2 | 1/4 | 1/2 | 0/4 |
| StomatitisGastrointestinal disorders | 0/6 | 1/15 | 1/5 | 1/3 | 0/2 | 0/4 | 0/2 | 0/4 |
| ConstipationGastrointestinal disorders | 0/6 | 0/15 | 0/5 | 1/3 | 0/2 | 0/4 | 0/2 | 0/4 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/15 | 0/5 | 1/3 | 0/2 | 0/4 | 0/2 | 0/4 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/15 | 0/5 | 1/3 | 0/2 | 0/4 | 0/2 | 0/4 |
| Event | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF |
|---|---|---|---|---|---|---|---|---|
| StomatitisGastrointestinal disorders | 1/6 | 9/15 | 2/5 | 1/3 | 0/2 | 1/4 | 1/2 | 4/4 |
| NeutropeniaBlood and lymphatic system disorders | 6/6 | 9/15 | 5/5 | 3/3 | 2/2 | 4/4 | 2/2 | 2/4 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 6/15 | 3/5 | 3/3 | 1/2 | 3/4 | 1/2 | 1/4 |
| LeukopeniaBlood and lymphatic system disorders | 1/6 | 4/15 | 2/5 | 1/3 | 1/2 | 2/4 | 2/2 | 1/4 |
| FatigueGeneral disorders | 3/6 | 10/15 | 4/5 | 1/3 | 2/2 | 1/4 | 2/2 | 2/4 |
| DysgeusiaNervous system disorders | 4/6 | 5/15 | 3/5 | 1/3 | 2/2 | 0/4 | 0/2 | 2/4 |
| Peripheral sensory neuropathyNervous system disorders | 3/6 | 5/15 | 0/5 | 0/3 | 2/2 | 0/4 | 0/2 | 0/4 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/6 | 7/15 | 3/5 | 1/3 | 2/2 | 1/4 | 1/2 | 2/4 |
| Rash pruriticSkin and subcutaneous tissue disorders | 0/6 | 2/15 | 0/5 | 0/3 | 0/2 | 0/4 | 2/2 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 5/15 | 1/5 | 0/3 | 0/2 | 1/4 | 2/2 | 1/4 |
Safety Population included all participants who received at least 1 dose of any study drug.
| Age, Continuous(years) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.7 ± 5.20 | 61.5 ± 13.10 | 60.2 ± 16.75 | 61.3 ± 8.62 | 56.5 ± 2.12 | 54.8 ± 18.73 | 52.5 ± 26.16 | 62.3 ± 25.71 | 60.4 ± 14.07 |
| Sex: Female, Male(Participants) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 4 | 1 | 1 | 1 | 1 | 2 | 1 | 11 |
| Male | 6 | 11 | 4 | 2 | 1 | 3 | 0 | 3 | 30 |
| Race/Ethnicity, Customized(participants) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 5 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Not Hispanic or Latino | 6 | 10 | 5 | 3 | 1 | 3 | 1 | 4 | 33 |
| Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 6 | 15 | 5 | 2 | 2 | 3 | 2 | 3 | 38 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 6 | 15 | 5 | 3 | 2 | 4 | 2 | 4 | 41 |
| Height(cm) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 185.5 ± 11.02 | 170.5 ± 10.04 | 177.2 ± 12.13 | 171.0 ± 10.08 | 174.5 ± 0.71 | 172.5 ± 10.98 | 155.6 ± 8.08 | 174.9 ± 6.99 | 173.6 ± 11.32 |
| Weight(kg) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 100.25 ± 15.842 | 82.73 ± 16.963 | 94.15 ± 25.623 | 87.73 ± 31.987 | 76.90 ± 8.344 | 85.97 ± 15.987 | 62.05 ± 11.950 | 87.05 ± 21.025 | 86.50 ± 19.550 |
| Body Surface Area (BSA)(m^2) | Alisertib 10 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 20 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 | Alisertib 30 mg (7D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 60 mg/m^2 | Alisertib 30 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Alisertib 40 mg (5D) + Docetaxel 75 mg/m^2 + GCSF | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 2.269 ± 0.2329 | 1.973 ± 0.2533 | 2.138 ± 0.3541 | 2.025 ± 0.4316 | 1.929 ± 0.1009 | 2.026 ± 0.2420 | 1.635 ± 0.2005 | 2.046 ± 0.2945 | 2.034 ± 0.2878 |
Ran from Aug 2010 to primary completion in Feb 2014, 42 months.
Results were first posted in Feb 2019, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →